• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

    2/14/24 6:16:06 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IOVA alert in real time by email
    SC 13G/A 1 p24-0297sc13ga.htm IOVANCE BIOTHERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Iovance Biotherapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.000041666 per share

    (Title of Class of Securities)
     

    462260100

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 46226010013G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 46226010013G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 46226010013G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Cubist Systematic Strategies, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    468,821

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    468,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    468,821

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.2%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 46226010013G/APage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    468,821

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    468,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    468,821

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.2%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 46226010013G/APage 6 of 8 Pages

     

     

    Item 1(a). Name of Issuer.
      Iovance Biotherapeutics, Inc. (the “Issuer”).
       
    Item 1(b). Address of Issuer's Principal Executive Offices.
      825 Industrial Road, Suite 400, San Carlos, CA 94070.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.000041666 per share (“Shares”), of the Issuer that were held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares that were held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares that were beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc., and with respect to Shares beneficially owned by Cubist Systematic Strategies.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.000041666 per share.

     

    Item 2(e). CUSIP Number.
      462260100

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

     

    CUSIP No. 46226010013G/APage 7 of 8 Pages

     

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on December 31, 2023.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
       
    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
       
    Item 6 Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
      Not applicable.
       
    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 46226010013G/APage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
         
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
         
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      CUBIST SYSTEMATIC STRATEGIES, LLC
       
         
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

      STEVEN A. COHEN
         
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

    Get the next $IOVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOVA

    DatePrice TargetRatingAnalyst
    5/16/2025$2.00Buy → Neutral
    UBS
    5/12/2025Buy → Hold
    Truist
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    10/24/2024$17.00Buy
    UBS
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    11/20/2023$12.00Buy
    Goldman
    9/18/2023$40.00 → $18.00Overweight
    Barclays
    5/30/2023$11.00 → $17.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 15, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 278,770 shares of Iovance's common stock to 59 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 202

      5/16/25 5:30:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

      SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025

      4/23/25 4:15:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Iovance Biotherapeutics Inc.

      SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      5/15/25 4:30:04 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Iovance Biotherapeutics Inc.

      10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 5:15:56 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 4:05:33 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/16/25 4:05:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Regulatory Officer Puri Raj K. converted options into 8,334 shares and covered exercise/tax liability with 2,509 shares, increasing direct ownership by 3% to 201,252 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/18/25 8:30:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Interim CEO & General Counsel Vogt Frederick G

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:49 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/16/25 4:05:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcpeak Merrill A bought $2,287,500 worth of shares (250,000 units at $9.15), increasing direct ownership by 356% to 320,150 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 7:52:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dukes Iain D. bought $292,800 worth of shares (32,000 units at $9.15), increasing direct ownership by 145% to 54,000 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 4:21:48 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iovance Biotherapeutics downgraded by UBS with a new price target

      UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

      5/16/25 8:01:50 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Truist

      Truist downgraded Iovance Biotherapeutics from Buy to Hold

      5/12/25 8:21:43 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Citizens JMP

      Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform

      5/9/25 8:42:44 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Financials

    Live finance-specific insights

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

      Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym

      11/7/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      10/18/24 8:38:16 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      3/19/24 5:19:45 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care